Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: A cost-minimization analysis

Pharmacotherapy

Volumn 23, Issue 3, 2003, Pages 301-309

  Boucher, Michel ^a,c   Rodger, Marc ^a   Johnson, Jeffrey A ^b   Tierney, Mike ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Canadian Coordinating Office for Health Technology Assessment   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ADULT; AMBULATORY SURGERY; ARTICLE; BLEEDING; CANADA; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; FINANCIAL MANAGEMENT; HOSPITAL MANAGEMENT; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; LUNG EMBOLISM; MALE; OUTPATIENT; PATIENT CARE; PATIENT REFERRAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; THROMBOSIS;

AMBULATORY CARE; CANADA; CASE-CONTROL STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; VENOUS THROMBOSIS;

EID: 0344407458     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.3.301.32102     Document Type: Article

References (37)

1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1:1309-12.
2. Baron RM, Goldhaber SZ. Deep vein thrombosis: outpatient management is now FDA approved. J Thromb Thrombolysis 1999;7:113-22.
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:S64-94.
4. Weitz J. Low-molecular-weight heparin. N Engl J Med 1997;337:688-98.
5. Rodger M, Bredeson C, Wells P, Beck J, Kearns B, Huebsch L. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in the treatment of deep vein thrombosis. Can Med Assoc J 1998:159:931-8.
6. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334:677-81.
7. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutanous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW, eds. Basic types of economic evaluation. In: Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press, 1997:6-17.
9. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
10. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:S176-93.
11. Potvin K. Case costing: a guide for the development of a pharmacy system. Hosp Pharm Prac 1998;5:1-9.
12. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
13. Ontario Ministry of Health and Long-Term Care. Schedule of benefits (April 1999). Toronto: The Ministry, 1999.
14. Statistics Canada. The consumer price index. Cat. no. 62-001-XPB. Ottawa: Statistics Canada, 2001.
15. Pagano M, Gauvreau K, ed. Confidence intervals. In: Principles of biostatistics, 2nd ed. Pacific Grove, CA: Duxbury, Thomson Learning, 2000:214-30.
16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW, ed. Cost-effectiveness analysis: what are the main points to consider when undertaking a sensitivity analysis? In: Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press, 1997:109-12.
17. Erdman SM, Rodvold KA, Friedenberg WR. Thromboembolic disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 3rd ed. Stamford, CT: Appleton & Lange, 1997:399-433.
18. Rodger M, Bredeson C, Wells P, Beck J, Kearns B, Huebsch L. Cost-effectiveness of low molecular weight heparin and unfractionated heparin in the treatment of deep vein thrombosis [online exclusive article]. Available from www.hematology.ogh.on.ca/lmwh/method.htm. Accessed June 9, 1999.
19. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
20. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med 1998;158:1809-12.
21. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep vein thrombosis with low molecular weight heparin. Arch Intern Med 1998;158:2001-3.
22. Groce JB. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy 1998;18(6 pt 3):S175-80.
23. O'Shaughnessy DF, Tovey C, Miller ALC, et al. Outpatient management of deep vein thrombosis. J Accid Emerg Med 1998;15:292-3.
24. Cook TF, Zed PJ, Busser JR, Filiatrault L. Outpatient treatment of deep vein thrombosis from the emergency department: clinical outcomes, patient satisfaction and economic analysis [abstr]. J Infect Pharmacother 2000;1:402.
25. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.
26. Bick RL. Low molecular weight heparins in the outpatient management of venous thromboembolism. Semin Thromb Hemost 1999;25:97-9.
27. Boccalon H, Elias A, Chalé JJ, Cadène A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin. Arch Intern Med 2000;160:1769-73.
28. Bellenger L. Traitement ambulatoire des thromboses veineuses profondes: a partir de données d'une étude portant sur 108 patients, évaluation de son coût et de son efficacité. Phlébologie 1992;45:447-51.
29. Frank D, Blättler W. Vergleich von ambulanter und stationärer behandlung der akuten tiefen beinvenenthrombose: subjektive und ökonomische aspekte. Schweiz Med Wochenschr 1998;128:1328-33.
30. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395-401.
31. Goldhaber SZ, Morrison RB, Diran LL, Creager MA, Lee TH Jr. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Arch Intern Med 1998;158:2325-8.
32. Osterkorn D, Schramm W, Szucs T. Gesundheitsökonomische evaluation der behundlung venöser thrombosen mit intravenösem unfraktioniertem heparin stationär versus subkutanem niedermolekularem heparin zu hause. Med Klin 1996;91:607-9.
33. van den Belt AGM, Bossuy PMM, Prins MH, Gallus AS, Büller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: an economic evaluation. Thromb Haemost 1998;79:259-63.
34. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-94.
35. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low- molecular-weight heparins compared to unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
36. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Ann Intern Med 1999;159:2298-304.
37. Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med 2000;15:108-15.